Last reviewed · How we verify
Combination therapy (COMB) — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Combination therapy (COMB) (Combination therapy (COMB)) — Ann & Robert H Lurie Children's Hospital of Chicago. A combination therapy approach that uses multiple agents together to enhance therapeutic efficacy, though the specific components and their mechanisms are not publicly detailed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Combination therapy (COMB) TARGET | Combination therapy (COMB) | Ann & Robert H Lurie Children's Hospital of Chicago | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Combination therapy (COMB) CI watch — RSS
- Combination therapy (COMB) CI watch — Atom
- Combination therapy (COMB) CI watch — JSON
- Combination therapy (COMB) alone — RSS
Cite this brief
Drug Landscape (2026). Combination therapy (COMB) — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-therapy-comb. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing